Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

NCT01565538 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Pemetrexed

Sponsor

Si-Yu Wang